Mountain Valley MD Holdings WKN: A2P082 ISIN: CA62430M1014 Kürzel: MVMD Forum: Aktien Thema: Hauptdiskussion

Ich habe hier auch ein gutes Gefühl das es noch was wird 🙂

In den letzten tagen waren einige filme im TV zu sehen , die sich mit der Problematik der Zulassung eines Wirkstoffes zu irgendeiner Krankheit beschäftigt. Es wird darin gezeigt welche Hürden genommen werden müssen, und wie Wettbewerber Alles versuchen dieses Neue Medikament nicht auf den Markt kommen zu lassen. Dies ist ein Milliardengeschäft . Da geht man auch bis zum äußersten!!! Ich glaube weiterhin an M V H D obwohl sie selber nichts herstellen.Sie haben aber viele Patente für Mensch und Tier gegen sehr viele Krankheiten im Portfolio. Lest Euch mal ein, und bildet euch dann wine Meinung! 🍀🍀🍀🤮 Gruß Geri

@Michi3110 , ich sehe das Sie sich über die Aktie gut informiert haben und meine denkweise sehr unterstützen? Uns viel Erfolg mit MVHD 🍀🍀🍀

Januar 2018 und Februar 2021 wurden jeweils Höchststände erreicht. Vielleicht kommt es diesmal auch mit dem 3-Jahreszyklus hin und wir erreichen im März 2024 höhere Kurse.

du hast so viel geschrieben, da hätten alle Kurse drauf gepasst, nach der 100 Tage oder 200 Tageslinie gab es nur eine Richtung

@Donleony, schau was ich am 13.Dezember geschrieben habe

Hi Geri, na wo ist deine Kursexplosion?

@Daxfee, danke für die Infos . geri

wie immer von einem guten plus zum abend hin ins minus gewandert. So wird es weitergehen bis ???????.

Mountain Valley is building a world-class organization centred around the implementation, licensing and reselling of key technologies and formulations: Patented Quicksome oral formulation and delivery technologies; Patented Quicksol solubility formulation technology; Licensed product reseller of Agrarius, a novel agricultural plant signalling technology.

Hier nochmal das Firmenziel/Technology:

Mountain Valley appoints Yao as CFO; Letellier resigns 2023-12-15 16:49 ET - News Release Mr. Dennis Hancock reports MOUNTAIN VALLEY MD ANNOUNCES PLANNED APPOINTMENT OF NEW CFO EFFECTIVE JANUARY 15, 2024 Mountain Valley MD Holdings Inc. has appointed Yong Yao to the role of chief financial officer, effective Jan. 15, 2024. The company has accepted the resignation of the company's current chief financial officer, Lucie Letellier, due to health issues that have resurfaced and require Ms. Letellier to take a leave of absence from her professional endeavours at this time. Ms. Letellier will continue to serve as the company's chief financial officer until Jan. 15, 2024, and assist with the transition to the new CFO. "I am very pleased to welcome Yong Yao to the MVMD team to support our commercialization growth phase and the scaling of our operations globally," said Dennis Hancock, president and chief executive officer of the company. "Mr. Yao is a very accomplished CFO and has joined us at a very important time as we navigate complex international sales, royalty and tax strategies." With a distinguished financial career spanning premier institutions in both North America and the Far East, Mr. Yao is a seasoned CFO and brings a wealth of expertise in financial markets, corporate governance and international business. In his recent role as CFO of Hanalytics BioMind Co., Mr. Yao played a pivotal role in securing $200-million (U.S.) in private equity financing and chartering the company's profitable growth to a valuation of $1.4-billion (U.S.). Mr. Yao was the executive director of Xinyuan Real Estate Corp. and president of Xin Yan Capital, a Xinyuan subsidiary, where he managed private equity funds totalling 30 billion Chinese yuan, facilitating successful initial public offerings, overseeing global land acquisition and real estate projects. Mr. Yao's leadership roles at Bank of America Merrill Lynch, Morgan Stanley and Scotia Bank Canada showcased his diverse abilities, including strategic financial oversight, implementation of accounting policies and international financial reporting standards, regulatory reporting, management reporting, and financial business planning. Notably, his entrepreneurial venture, Selectin Biomedical Inc., secured substantial financing and regulatory approvals for innovative small-molecule chemical drugs designed for anti-tumour applications. Mr. Yao holds an MBA from McGill University and two designations by AICPA-CIMA U.K., including fellow chartered management accountant (FCMA) and chartered global management accountant (CGMA). Additionally, he holds a bachelor of science degree in biology from Nankai University. The company has granted stock options to Mr. Yao, in accordance with the terms and conditions of the company's stock option plan, to purchase 500,000 common shares in the capital stock of the company. The options are exercisable for a period of five years from the date of grant at a price of five cents per share. The options will vest 20 per cent on the date of grant, 30 per cent on the six-month anniversary following the date of grant and the remaining 50 per cent on the 12-month anniversary following the date of grant. The company extends its appreciation to outgoing CFO Ms. Letellier for her contributions to the company. "Seeing the relapse in Lucie Letellier's health is very unfortunate, and we respect the important need for her to focus on her well-being with her family at this time," continued Mr. Hancock. "We are grateful for her support of MVMD and willingness to manage through this transition window to minimize any potential disruption to the business."

Hier mal ein paar neue Nachrichten..CFO Wechsel...Frohe Weihnachten an alle.

@Geri0815

Gei, danke wünsch ich dir auch, aber was gibt es denn Bahnbrechendes bis März was den Kurs bis dahin antreiben soll?

@ Donleony, alles gut . Kommen Sie gut und gesund über die Feiertage, im februar- März sehen wir , wie weit der Kurs bis dahin Richtung Norden gewandert ist. Glückauf 🍀